Abstract: The invention discloses an artificially synthesized peptide H-473 and use thereof. The peptide H-473 has an amino acid sequence of RGLRGLR, a molecular weight of 827 Da and a PI of 12.30. The invention further discloses use of the peptide H-473 in anti-cancer, anti-senile dementia, analgesia and the like. The peptide H-473 provides scientific basis and direction for research and development of anti-cancer, anti-asthma, anti-senile dementia and analgesia, provides a valuable resource for studying mechanisms of anti-cancer, anti-asthma, anti-senile dementia, analgesia and anti-psoriasis, and provides a new direction for researching novel means for anti-cancer, anti-asthma, anti-senile dementia, analgesia, anti-psoriasis and anti-age-related macular degeneration (AMD).

Abstract: Disclosed are compounds of Formula I, or a salt thereof cyclic polypeptide of Formula I: Formula I where A, B, E, R4, and R8 are as defined herein, which compounds have properties for antagonizing PCSK9. Also described are pharmaceutical formulations comprising the compounds of Formula I or their salts, and methods of treating cardiovascular disease and conditions related to PCSK9 activity, e.g.

Abstract: The present invention relates to a compound represented by formula I: and pharmaceutically acceptable salts thereof. The compounds of formula I are inhibitors of diacylglyceride O-acyltransferase 2 (“DGAT2”) and may be useful in the treatment, prevention and suppression of diseases mediated by DGAT2. The compounds of the present invention may be useful in the treatment of hepatic steatosis, diabetes mellitus, obesity, hyperlipidemia, hypercholesterolemia, atherosclerosis, nonalcoholic steatohepatitis (NASH), cardiorenal diseases such as chronic kidney diseases and heart failure and related diseases and conditions.

Abstract: Disclosed are compounds of Formula A, or a pharmaceutically acceptable salt thereof: where A, X, R1, and R2 are as defined herein, which compounds have properties for antagonizing PCSK9. Also described are pharmaceutical formulations comprising the compounds of Formula I or their salts, and methods of treating cardiovascular disease and conditions related to PCSK9 activity, e.g. atherosclerosis, hypercholesterolemia, coronary heart disease, metabolic syndrome, acute coronary syndrome, or related cardiovascular disease and cardiometabolic conditions.

Abstract: A haptic feedback method for a touch display screen of a vehicle is disclosed. The method includes: acquiring a touch operation of a user from the touch display screen of the vehicle; determining a type of the acquired touch operation, and retrieving a pre-stored feedback signal corresponding to the type of the touch operation, wherein different types of the touch operations correspond to different feedback signals; and transmitting the corresponding feedback signal to an actuator, and driving the actuator to vibrate by using the feedback signal for providing haptic feedback. A haptic feedback system and a haptic feedback control device are also provided.

Abstract: The present invention relates to biaryl monobactam compounds of Formula I and pharmaceutically acceptable salts thereof, wherein X, Y, Z, A1, Q, A2, M, W, RX and Rz are as defined herein. The present invention also relates to compositions which comprise a biaryl monobactam compound of the invention or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. The invention further relates to methods for treating a bacterial infection comprising administering to the patient a therapeutically effective amount of a compound of the invention, either alone or in combination with a therapeutically effective amount of a second beta-lactam antibiotic.

Abstract: Novel compounds of the structural formula I, and the pharmaceutically acceptable salts thereof, are inhibitors of TarO and may be useful in the prevention, treatment and suppression of diseases mediated by TarO, such as bacterial infections, including gram negative bacterial infections and gram positive bacterial infections such as MRSA and MRSE, alone or in combination with a ?-lactam antibiotic.

Abstract: A method and apparatus for human-machine interaction, a terminal, and a computer-readable storage medium are provided. The method for human-machine interaction of the present disclosure includes: receiving interaction information of a user acquired by a sensor, wherein the sensor includes a sensor that acquires the interaction information by means of a touch manner; determining a reply control signal corresponding to the interaction information, wherein the reply control signal includes a tactile reply control signal and a visual reply control signal; and generating a tactile reply response according to the tactile reply control signal, and generating a visual reply response according to the visual reply control signal, wherein the tactile reply response is used to provide the user with a response action for a tactile stimulus, and the visual reply response is used to provide the user with a visible response action.

Abstract: The present disclosure relates to the technical field of electronic products, and discloses an electronic device, a key assembly, and a key control method. In the embodiment of the invention, the key assembly includes a key housing, a sensing element, a base, a linear motor and an elastic member. The sensing element is disposed on a surface of the key housing. The key housing is disposed on the base through the elastic member. The linear motor is disposed on the key housing and faces the base. The sensing element and the linear motor are respectively electrically connected to a processor of the electronic device. The processor is configured to acquire a vibration mode corresponding to the sensed data, and control the linear motor to vibrate according to the vibration mode. The embodiment of the present disclosure further provides a key control method and an electronic device.

Abstract: A method and apparatus for human-machine interaction, a terminal, and a computer-readable storage medium are provided. The method for human-machine interaction is applied to the terminal, and includes: acquiring an audio signal; and generating a tactile sensing signal and a visual sensing signal according to the audio signal. The tactile sensing signal is used for providing a tactile stimulus to a user, and the visual sensing signal is used for providing a visual stimulus to the user. The terminal generates the tactile sensing signal for providing the user with the tactile stimulus and the visual sensing signal for providing the user with the visual stimulus according to the acquired audio signal, so as to enable the user to obtain different sensory experiences, enhance the sense of participation of the user, and improve the experience of the user.

Abstract: A haptic feedback method for a touch display screen of a vehicle is disclosed. The method includes: acquiring a touch operation of a user from the touch display screen of the vehicle; determining a type of the acquired touch operation, and retrieving a pre-stored feedback signal corresponding to the type of the touch operation, wherein different types of the touch operations correspond to different feedback signals; and transmitting the corresponding feedback signal to an actuator, and driving the actuator to vibrate by using the feedback signal for providing haptic feedback. A haptic feedback system and a haptic feedback control device are also provided.

Abstract: In the field of mobile devices, a motor driving method, a terminal device, and a computer-readable storage medium are disclosed. In the present disclosure, a current state of an application target in a current running program is obtained in real-time, a drive signal is generated according to the current state of the application target and is used to drive a motor to produce a vibration sensation corresponding to the current state, and the motor is driven to vibrate according to the generated drive signal. In this way, the motor vibration can be dynamically changed in real time as the use scenario of the mobile terminal changes.

Abstract: Disclosed are compounds of Formula I, or a salt thereof: where A, B, D, X, R1, R2 and R8 are as defined herein, which compounds have properties for antagonizing PCSK9. Also described are pharmaceutical formulations comprising the compounds of Formula I or their salts, and methods of treating cardiovascular disease and conditions related to PCSK9 activity, e.g. atherosclerosis, hypercholesterolemia, coronary heart disease, metabolic syndrome, acute coronary syndrome, or related cardiovascular disease and cardiometabolic conditions.

Abstract: The present invention relates to a compound represented by formula I: and pharmaceutically acceptable salts thereof. The compounds of formula I are inhibitors of diacylglyceride O-acyltransferase 2 (“DGAT2”) and may be useful in the treatment, prevention and suppression of diseases mediated by DGAT2. The compounds of the present invention may be useful in the treatment of hepatic steatosis, diabetes mellitus, obesity, hyperlipidemia, hypercholesterolemia, atherosclerosis, nonalcoholic steatohepatitis (NASH), cardiorenal diseases such as chronic kidney diseases and heart failure and related diseases and conditions.

Abstract: The present invention relates to bicyclic aryl monobactam compounds of Formula (I), and pharmaceutically acceptable salts thereof, wherein A1, L, M, W, X, Y, Z, RX and Rz are as defined herein. The present invention also relates to compositions which comprise a bicyclic aryl monobactam compound of the invention or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. The invention further relates to methods for treating a bacterial infection comprising administering to the patient a therapeutically effective amount of a compound of the invention, either alone or in combination with a therapeutically effective amount of one or more beta-lactamase inhibitor compounds.

Abstract: The present invention relates to bicyclic aryl monobactam compounds of Formula (I), and pharmaceutically acceptable salts thereof, wherein A1, L, M, W, X, Y, Z, RX and Rz are as defined herein. The present invention also relates to compositions which comprise a bicyclic aryl monobactam compound of the invention or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. The invention further relates to methods for treating a bacterial infection comprising administering to the patient a therapeutically effective amount of a compound of the invention, either alone or in combination with a therapeutically effective amount of one or more beta-lactamase inhibitor compounds.

Abstract: The present invention provides compounds of Formula (I) and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and chronic kidney disease and conditions associated with excessive salt and water retention.

Abstract: The present invention relates to biaryl monobactam compounds of Formula I: and pharmaceutically acceptable salts thereof, wherein X, Y, Z, A1, Q, M, W, RX and Rz are as defined herein. The present invention also relates to compositions which comprise a biaryl monobactam compound of the invention or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. The invention further relates to methods for treating a bacterial infection comprising administering to the patient a therapeutically effective amount of a compound of the invention, either alone or in combination with a therapeutically effective amount of a second beta-lactam antibiotic.

Abstract: The present invention provides compounds of Formula (I) (Formula (I)) including pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and chronic kidney disease and conditions associated with excessive salt and water retention.

Abstract: The present invention provides compounds of Formula I and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and chronic kidney disease and conditions associated with excessive salt and water retention.